Assessing Lung Cancer Screening Eligibility of Patients With Lung Cancer in the Boston Lung Cancer Study: An Analysis of 7186 Lung Cancer Cases

IF 3.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Annals of Thoracic Surgery Pub Date : 2025-01-24 DOI:10.1016/j.athoracsur.2025.01.003
Alexandra L. Potter BS , Quiana Guo , Deepti Srinivasan BS , Margaret E. Yang BS , Meghan McCarthy BS , Danny Wang MD , Jui Kothari MS , Andrea Shafer MA, MPH , David C. Christiani MD, MPH , Chi-Fu Jeffrey Yang MD
{"title":"Assessing Lung Cancer Screening Eligibility of Patients With Lung Cancer in the Boston Lung Cancer Study: An Analysis of 7186 Lung Cancer Cases","authors":"Alexandra L. Potter BS ,&nbsp;Quiana Guo ,&nbsp;Deepti Srinivasan BS ,&nbsp;Margaret E. Yang BS ,&nbsp;Meghan McCarthy BS ,&nbsp;Danny Wang MD ,&nbsp;Jui Kothari MS ,&nbsp;Andrea Shafer MA, MPH ,&nbsp;David C. Christiani MD, MPH ,&nbsp;Chi-Fu Jeffrey Yang MD","doi":"10.1016/j.athoracsur.2025.01.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>This study sought to evaluate the proportion of patients with lung cancer who would have qualified for lung cancer screening under different eligibility criteria in the Boston Lung Cancer Study (BLCS).</div></div><div><h3>Methods</h3><div>BLCS participants with a diagnosis of lung cancer from 1992 to 2024 were identified for analysis. The study evaluated the proportion of patients who would have qualified for screening under the 2021 US Preventive Services Task Force (USPSTF) (age 50-80 years, ≥20-pack-years, &lt;15 quit-years), 20-year duration (age 50-80 years, ≥20-year smoking duration, &lt;15 quit-years), American Cancer Society (age 50-80 years, ≥20-pack-years), National Comprehensive Cancer Network (NCCN) category A (age ≥50 years, ≥20-pack-years), and NCCN category AB (age ≥50 years, ≥20-pack-years <em>or</em> ≥20-year smoking duration) guidelines. The study also evaluated the proportion of patients with a smoking history who were ineligible for screening under the aforementioned guidelines and who had a PLCOm2012 risk score ≥1.0% (referred to as the “PLCOm2012 1.0% risk threshold”). The PLCOm2012 model is a lung cancer risk prediction model developed using data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.</div></div><div><h3>Results</h3><div>Of 7186 patients meeting inclusion criteria, 33.4% currently smoked, 52.1% formerly smoked, and 14.5% had never smoked. Among these patients, 46.1% met the USPSTF guideline, 48.9% met the 20-year duration guideline, 61.0% met the American Cancer Society guideline, 66.1% met the NCCN category A guideline, and 71.7% met the NCCN category AB guideline. Although the PLCOm2012 1.0% risk threshold identified 52.2% of patients with a smoking history who were ineligible for screening under the USPSTF guideline, the PLCOm2012 1.0% risk threshold excluded the majority of patients with &lt;20 pack-years.</div></div><div><h3>Conclusions</h3><div>In this analysis of 7186 patients with lung cancer, only 46.1% would have met the USPSTF guideline. Including a smoking duration criterion and removing the 15-years-since-quitting criterion from the USPSTF guideline would increase the proportion of patients eligible for screening.</div></div>","PeriodicalId":50976,"journal":{"name":"Annals of Thoracic Surgery","volume":"119 4","pages":"Pages 768-776"},"PeriodicalIF":3.9000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Thoracic Surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0003497525000670","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

This study sought to evaluate the proportion of patients with lung cancer who would have qualified for lung cancer screening under different eligibility criteria in the Boston Lung Cancer Study (BLCS).

Methods

BLCS participants with a diagnosis of lung cancer from 1992 to 2024 were identified for analysis. The study evaluated the proportion of patients who would have qualified for screening under the 2021 US Preventive Services Task Force (USPSTF) (age 50-80 years, ≥20-pack-years, <15 quit-years), 20-year duration (age 50-80 years, ≥20-year smoking duration, <15 quit-years), American Cancer Society (age 50-80 years, ≥20-pack-years), National Comprehensive Cancer Network (NCCN) category A (age ≥50 years, ≥20-pack-years), and NCCN category AB (age ≥50 years, ≥20-pack-years or ≥20-year smoking duration) guidelines. The study also evaluated the proportion of patients with a smoking history who were ineligible for screening under the aforementioned guidelines and who had a PLCOm2012 risk score ≥1.0% (referred to as the “PLCOm2012 1.0% risk threshold”). The PLCOm2012 model is a lung cancer risk prediction model developed using data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Results

Of 7186 patients meeting inclusion criteria, 33.4% currently smoked, 52.1% formerly smoked, and 14.5% had never smoked. Among these patients, 46.1% met the USPSTF guideline, 48.9% met the 20-year duration guideline, 61.0% met the American Cancer Society guideline, 66.1% met the NCCN category A guideline, and 71.7% met the NCCN category AB guideline. Although the PLCOm2012 1.0% risk threshold identified 52.2% of patients with a smoking history who were ineligible for screening under the USPSTF guideline, the PLCOm2012 1.0% risk threshold excluded the majority of patients with <20 pack-years.

Conclusions

In this analysis of 7186 patients with lung cancer, only 46.1% would have met the USPSTF guideline. Including a smoking duration criterion and removing the 15-years-since-quitting criterion from the USPSTF guideline would increase the proportion of patients eligible for screening.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在波士顿肺癌研究中评估肺癌患者的肺癌筛查资格:对7186例肺癌病例的分析
背景:评估波士顿肺癌研究(BLCS)中符合不同资格标准的肺癌患者进行肺癌筛查的比例。方法:选取1992-2024年间诊断为肺癌的BLCS参与者进行分析。根据2021年美国预防服务工作组(USPSTF)(年龄50-80岁,>0包年,20包年),nccn - a类(年龄>0岁,>0包年)和nccn - ab类(年龄>0岁,>20包年或>20包年)指南评估有资格进行筛查的患者比例。我们还评估了有吸烟史但PLCOm2012风险评分为1.0%的患者在上述指南下不适合筛查的比例。结果:在7186例符合纳入标准的患者中,33.4%目前吸烟,52.1%曾经吸烟,14.5%从未吸烟。在这些患者中,46.1%符合USPSTF指南,48.9%符合20年持续时间指南,61.0%符合美国癌症协会指南,66.1%符合nccn - a类指南,71.7%符合nccn - ab类指南。PLCOm2012 1.0%的风险阈值确定了52.2%的有吸烟史的患者不符合USPSTF标准的筛查,而PLCOm2012 1.0%的风险阈值排除了大多数以下患者:结论:在对7186名肺癌患者的分析中,只有46.1%的患者符合USPSTF标准。从USPSTF指南中加入吸烟持续时间标准并删除戒烟15年的标准将增加有资格接受筛查的患者比例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Annals of Thoracic Surgery
Annals of Thoracic Surgery 医学-呼吸系统
CiteScore
6.40
自引率
13.00%
发文量
1235
审稿时长
42 days
期刊介绍: The mission of The Annals of Thoracic Surgery is to promote scholarship in cardiothoracic surgery patient care, clinical practice, research, education, and policy. As the official journal of two of the largest American associations in its specialty, this leading monthly enjoys outstanding editorial leadership and maintains rigorous selection standards. The Annals of Thoracic Surgery features: • Full-length original articles on clinical advances, current surgical methods, and controversial topics and techniques • New Technology articles • Case reports • "How-to-do-it" features • Reviews of current literature • Supplements on symposia • Commentary pieces and correspondence • CME • Online-only case reports, "how-to-do-its", and images in cardiothoracic surgery. An authoritative, clinically oriented, comprehensive resource, The Annals of Thoracic Surgery is committed to providing a place for all thoracic surgeons to relate experiences which will help improve patient care.
期刊最新文献
Safety and Immediate Efficacy of Pulmonary Thromboendarterectomy for Chronic Thromboembolic Disease. Intraoperative Surgical Margin Assessment of Sublobar Lung Resection Specimens Using Computed Tomography. Prolonged Survival in Mesothelioma Patients Without Surgical Resection: A National Cancer Database Analysis. Primary Thoracic Synovial Sarcoma: Results of Treatment at a Single Institution. LVOT Modification During Robotic MV Repair: Clarifying Selection Criteria and Conduction Risks.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1